Furthermore, the expression of Plexin-B2 was positively correlated with seizure frequency in TSC and FCD IIb patients. In conclusion, our results showed the Plexin-B2-Sema4C system was abnormally expressed in cortical lesions of TSC and FCD IIb patients, signifying that the Plexin-B2-Sema4C system may play a role in the pathogenic development of TSC and FCD IIb.
By examining the clustering and colocalization of presynaptic and postsynaptic molecules, we seek to determine whether the unique transmembrane domains of Plexin-B1 and Plexin-B2 may direct distinct steps of GABAergic and glutamatergic synapse development. Uncovering the functions of specific Plexin-B domains in synapse development will enhance our understanding of the signaling mechanisms that govern different steps in this process, as well as provide insight on how those processes differ between GABAergic and glutamatergic synapse development.
"Avera Health...and Sema4...announced the Avera/Sema4 Oncology and Analytics Protocol (ASAP) study, a five-year commitment to population health for precision oncology care...Avera and Sema4 will leverage Sema4 Signal® Whole Exome/Transcriptome Sequencing (WES/WTS), which captures data from approximately 18,500 genes, to enable comprehensive molecular profiling of a patient’s tumor tissue. The ASAP study will also include Sema4 Signal® Hereditary Cancer, one of the most comprehensive hereditary cancer testing panels available, to inform better care decisions for individuals with and without a concurrent cancer diagnosis."
There were no FDA-approved SDTs in prostate cancer (PCa) until 2020, when PARP inhibitors olaparib and rucaparib were approved for tumors bearing homologous recombination repair (HRR) genes. Increases in NGS test volume and olaparib use coincided with approval of PARP inhibitors for HRR-mutated PCa patients. Notably, NGS was used to match patients to off-label/investigational olaparib before its FDA approval.
"Sema4...announced the nationwide expansion of its disparities in cancer care study. The study, launched in 2021, enables access to comprehensive genetic and genomic testing for advanced cancer patients in underserved communities...The REsearch to advance PREciSion medicine and health Equity in oNcology Treatment (REPRESENT) study, which is already enrolling patients at five locations across two sites, will run nationally in collaboration with community oncologists caring for patients with advanced cancer in diverse and traditionally understudied and underserved populations."